A Chinese delegation led by Vice Premier Liu He could be sent before month's end to iron out phase one, a source tells CNBC's Kayla Tausche.Marketsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Check out the companies making headlines in midday trading:Market Insiderread more
"I fear that's what we're headed into" here in America, warns the former Treasury secretary.Economyread more
"But I expect we'll have a deal," Mnuchin tells CNBC.Politicsread more
Kohl's stores are getting a bit of a refresh, and are being infused with new brands, ahead of this holiday season.Retailread more
Online travel company Booking Holdings has dropped out of Facebook's libra, joining a growing list of firms who have exited the embattled cryptocurrency project.Technologyread more
Apple will release the iPhone SE2 early next year for $399, analyst Ming-Chi Kuo says.Tech Driversread more
State polls show that Trump's standing has weakened in some states hurt by the trade war.2020 Electionsread more
Sanders, who is recovering from a heart attack, reveals the new tax plan a day before the third Democratic debate.2020 Electionsread more
White House press secretary Stephanie Grisham said in a Twitter post that while President Trump had not seen the video depicting him going on a bloody rampage in a so-called...Politicsread more
J.P. Morgan shared with its clients the firm's best current stock picks in the U.S. pharmaceuticals sector.
"We continue to see an attractive fundamental set-up for the Major Pharma group with an upward bias to EPS estimates and with the group still inexpensive in our view, trading at a significant discount to the broader market," the firm's pharmaceuticals research group said in a report Tuesday. "With valuation still inexpensive relative to the market in our view and healthy fundamentals, we continue to see opportunities in the group."
The analyst team noted pharma stocks are currently trading at about 15.1 times estimated 2018 earnings per share versus the 17.5 times for the S&P 500.
Here are three overweight-rated companies that made the J.P. Morgan's recommended list and their price targets.